During the World Economic Forum in Davos last week, Elon Musk called human aging a “very solvable” problem. The company announced on Tuesday that its planned clinical trials had been greenlit by the US Food and Drug Administration. As Tech Review points out, the approach comes with some inherent risks. However, Life Biosciences has already claimed that its approach is safe, pointing to experiments involving mice that had their vision restored after having their optic nerves damaged. “The optimistic case is this solves some blindness for certain people and catalyzes work in other indications,” biotech investor Karl Pfleger told Tech Review.